Latest Comments

Slow progress in pancreatic cancer treatment

Slow progress in pancreatic cancer treatment

Ophthalmology market is on the verge of a gene therapy breakthroug

Ophthalmology market is on the verge of a gene therapy breakthroug

Celgene’s CC-220 Phase IIa data boost prospect beyond skin in general lupus

Celgene’s CC-220 Phase IIa data boost prospect beyond skin in general lupus

Green light for TissueGene as Invossa gains approval in Korea

Green light for TissueGene as Invossa gains approval in Korea

UV-free tanning may prevent skin cancer

UV-free tanning may prevent skin cancer

Merck’s Oral Multiple Sclerosis Therapy Cladribine Finally Gains Support From EU Panel

Merck’s Oral Multiple Sclerosis Therapy Cladribine Finally Gains Support From EU Panel

Do new diabetes discoveries deliver more benefits than risks?

Do new diabetes discoveries deliver more benefits than risks?

Carefully stepping away from RCTS: clinical trial design in a new medical era

Carefully stepping away from RCTS: clinical trial design in a new medical era

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

Insulin-related therapy: despite advances, unmet needs remain

Insulin-related therapy: despite advances, unmet needs remain

EULAR 2017: Chondroitin Sulphate surprises with good results in knee osteoarthritis

EULAR 2017: Chondroitin Sulphate surprises with good results in knee osteoarthritis

Fecal transplant-based treatment for C. difficile reaches phase III trials

Fecal transplant-based treatment for C. difficile reaches phase III trials

Tempered optimism for early IDO + PD1 dual checkpoint blockade data in advanced urothelial carcinoma

Tempered optimism for early IDO + PD1 dual checkpoint blockade data in advanced urothelial carcinoma

The Three-Pronged Strategy to Combat NASH

The Three-Pronged Strategy to Combat NASH

Get Granular, Beat Cancer

Get Granular, Beat Cancer

Highlights from the 2017 ATS Conference – Positive results for Nucala marks strong potential for GSK to win the first approved biologic for eGPA

Highlights from the 2017 ATS Conference – Positive results for Nucala marks strong potential for GSK to win the first approved biologic for eGPA

New Data Released for Roche’s Latest Game-Changing Drug for Multiple Sclerosis

New Data Released for Roche’s Latest Game-Changing Drug for Multiple Sclerosis

Carcinoma Remains Predominant Histologic Subtype of Ovarian Cancer

Carcinoma Remains Predominant Histologic Subtype of Ovarian Cancer

Beyond the indefinite treatment of chronic lymphocytic leukemia

Beyond the indefinite treatment of chronic lymphocytic leukemia

Unmet needs in melanoma treatment

Unmet needs in melanoma treatment

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention